Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097725 | 0.96 | — | — | |
| SCHEMBL1746 | 0.96 | — | — | |
| SCHEMBL5544690 | 0.96 | MEN1 (0.42) | MEN1KMT2A | |
| Iodide SCHEMBL115029 | 0.92 | MEN1 (0.40) | MEN1KMT2A | |
| Fluoride SCHEMBL73855 | 0.92 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL319537 | 0.92 | MEN1 (0.40) | MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL1997314 | 0.92 | MEN1 (0.40) | MEN1KMT2A | |
| Fluoride SCHEMBL1025917 | 0.92 | MEN1 (0.40) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL22577541 | 0.92 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL3210291 | 0.92 | MEN1 (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3601297-B1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3601297-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | Amgen Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20190201412-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2019-07-04 | — | — | US | disclosed |
| CN-106977544-B | For treating the pantothenic acid ester derivant of neurological disease | 雷特罗芬公司 | 2019-06-07 | — | — | CN | disclosed |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
| CN-106977544-A | Pantothenic acid ester derivant for treating sacred disease | 雷特罗芬公司 | 2017-07-25 | — | — | CN | disclosed |
| US-9169283-B2 | Post-synthetic modification of nucleic acids by inverse diels-alder reaction | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20130085271-A1 | POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2013-04-04 | — | — | US | disclosed |
| EP-2565199-A1 | Multiple orthogonal labelling of oligonucleotides | Deutsches Krebsforschungszentrum (DE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2531514-A2 | POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION | Deutsches Krebsforschungszentrum (DE) | 2012-12-12 | — | — | EP | disclosed |
| EP-2360167-A1 | Post-synthetic modification of nucleic acids by inverse Diels-Alder reaction | Deutsches Krebsforschungszentrum (DE) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011095336-A2 | POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2011-08-11 | — | — | WO | disclosed |
| CN-1161336-C | Quinoline carboxamides as antiviral agents | �������Ŷ���Լ��������˾ | 2004-08-11 | — | — | CN | disclosed |
| EP-0994862-A2 | SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BEECHAM PLC (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999002502-A2 | SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BEECHAM PLC (GB) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201412-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | MEN1 761/4885KMT2A 1644/4885 |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | MEN1 761/4885KMT2A 1644/4885 |
| US-20130085271-A1 | POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION | DERA, ADAR, POLRMT | MEN1 616/4885KMT2A 240/4885 |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | MEN1 761/4885KMT2A 1644/4885 |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | MEN1 761/4885KMT2A 1644/4885 |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | MEN1 761/4885KMT2A 1644/4885 |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | MCL1, BCL9, BCL2L1 | MEN1 711/4885KMT2A 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.